United Therapeutics Corporation $UTHR Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 21.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,500 shares of the biotechnology company’s stock after selling 7,600 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund owned 0.06% of United Therapeutics worth $11,528,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. CWM LLC increased its position in shares of United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after buying an additional 3,487 shares in the last quarter. AXQ Capital LP grew its stake in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares during the last quarter. Osaic Holdings Inc. increased its holdings in United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after acquiring an additional 33,662 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in United Therapeutics during the third quarter worth about $8,351,000. Finally, Merit Financial Group LLC lifted its holdings in shares of United Therapeutics by 56.3% in the third quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company’s stock valued at $3,109,000 after purchasing an additional 2,672 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. UBS Group boosted their price target on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Stock Down 1.5%

UTHR stock opened at $464.93 on Friday. The stock has a market capitalization of $20.02 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 2.45 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The stock’s fifty day simple moving average is $486.85 and its 200-day simple moving average is $408.02.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the firm posted $6.39 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total transaction of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at $2,136,900. The trade was a 19.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total value of $3,900,087.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $17,283,024.09. This trade represents a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 597,814 shares of company stock valued at $280,924,148 in the last ninety days. 10.30% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.